Since it was first associated with schizophrenia (SCZ) in a 2011 genome-wide association study (GWAS), there have been over 100 publications focused on MIR137, the gene encoding microRNA-137. These studies have examined everything from its fundamental role in the development of mice, flies, and fish to the intriguing enrichment of its target gene network in SCZ. Indeed, much of the excitement surrounding MIR137 is due to the distinct possibility that it could regulate a gene network involved in SCZ etiology, a disease which we now recognize is highly polygenic. Here we comprehensively review, to the best of our ability, all published genetic and biological evidence that could support or refute a role for MIR137 in the etiology of SCZ. Through a careful consideration of the literature, we conclude that the data gathered to date continues to strongly support the involvement of MIR137 and its target gene network in neuropsychiatric traits, including SCZ risk. There remain, however, more unanswered than answered questions regarding the mechanisms linking MIR137 genetic variation with behavior. These questions need answers before we can determine whether there are opportunities for diagnostic or therapeutic interventions based on MIR137. We conclude with a number of suggestions for future research on MIR137 that could help to provide answers and hope for a greater understanding of this devastating disorder.
(e.g., age of onset, psychotic symptoms, and cognitive function) (Cummings et al., 2013; Kuswanto et al., 2015; Lett et al., 2013) , miR-137 expression in the brain (Guella et al., 2013 ), brain structure (Cousijn et al., 2014; Kelly et al., 2014; Kuswanto et al., 2015; Lett et al., 2013; Li & Su, 2013; Patel et al., 2015; Rose et al., 2014; Wright et al., 2016) , and brain activities (Liu et al., 2014; Mothersill et al., 2014; van Erp et al., 2014; Whalley et al., 2012) . These are summarized in Table 1 and will be discussed in this manuscript.
The haplotype block harboring MIR137 also contains a second miRNA gene (MIR2682) which has been reported to have very low brain expression (Miller et al., 2014) , explaining the little attention it has garnered, and the 5′ portion of the gene DPYD (encoding dihydropyrimidine dehydrogenase), which itself has an independent genome-wide significant association with SCZ in its 3′ region (Ripke, 2013 ; Schizophrenia Working Group of the Psychiatric Genomics Consortium, 2014) . Copy number variants (CNVs) in the region shown in Figure 1 are very rare, but have proven informative. In particular, hemizygous deletions in this region of chr1p21.3 encompassing both DPYD and MIR137 have been described in ∼10 cases and are associated with a syndrome consisting primarily of intellectual disability, autism-spectrum disorder (ASD), and obesity (Carter et al., 2011; D'Angelo, Moller Dos Santos, Alonso, & Koiffmann, 2015; Willemsen et al., 2011) . Some investigators initially proposed DPYD to be the major gene contributing to this syndrome (Carter et al., 2011; D'Angelo et al., 2015) , which seemed sensible since DPYD deficiency (OMIM #274270; DPYD encodes for the rate-limiting enzyme in the catabolism of the pyrimidine bases), an autosomal recessive disease, is characterized by childhood onset neurological problems, including developmental delay. Critically, however, two recent reports from Pinto et al. (2014) and Tucci, Ciaccio, Scuvera, Esposito, and Milani (2016) have identified children whose deletions in this region overlaps only MIR137, leaving DPYD unaffected. They both show that hemizygous loss of MIR137 alone is sufficient to produce all three features of this syndrome (intellectual disability, ASD, and obesity).
While these CNV data may seem to suggest that MIR137 is more relevant to ASD than SCZ, it is important to note that these case reports describe children who have yet to enter the risk period for SCZ and, of course, a one-copy deletion may lead to a more profound phenotype than common SNPs, which likely have a more subtle effect on function.
In support of this idea, the Cross-Disorder Group of the Psychiatric Genomics Consortium (PGC) reported that, in an analysis of five major psychiatric disorders, a best-fit model predicted common variants in MIR137 to jointly influence risk to SCZ and ASD, but not attention deficit hyperactivity disorder (ADHD), bipolar disorder, or major depression (Cross-Disorder Group of the Psychiatric Genomics Consortium, 2013).
| ESSENTIAL BACKGROUND ON microRNAs
MicroRNAs (miRNAs) are small non-coding RNA species of ∼22 nucleotides which negatively regulate mRNA stability or translation, and in turn, alter various cellular functions (Bartel, 2004; LagosQuintana, Rauhut, Lendeckel, & Tuschl, 2001; Wright, Turner, Calhoun, & Perrone-Bizzozero, 2013) . Importantly, a single miRNA can regulate the expression of many target genes, and, as such, miRNAs often act as key signaling nodes regulating complex biological networks.
The canonical miRNA biogenesis process is nicely summarized in previous articles (Bartel, 2004; Kim & Kim, 2007; Lagos-Quintana et al., 2001; Wright et al., 2013) . In short, miRNAs are transcribed from intergenic non-coding RNA (such is the case for miR-137) or introns of protein coding genes (introgenic microRNA) (Kim, Han, & Siomi, 2009; Liu et al., 2008) . The single-stranded "primary" miRNA forms a stemloop structure and is then cleaved in the nucleus into a ∼70 nucleotide "precursor" miRNAs by a complex composed of Drosha and DGCR8 (Denli, Tops, Plasterk, Ketting, & Hannon, 2004; Gregory et al., 2004; Han et al., 2006) . Following export to the cytoplasm, the precursor miRNA is further processed by Dicer into its final ∼22 nucleotide form (Chendrimada et al., 2005; Forstemann et al., 2005) . Finally, miRNAs are loaded onto the RNA-induced silencing complex (RISC) where they bind to their target RNAs, induce mRNA degradation and/or reduce translation efficiency (Wightman, Ha, & Ruvkun, 1993; Wu & Belasco, 2008; Zeng, Yi, & Cullen, 2003) .
| miRNAs ARE ESSENTIAL FOR PROPER BRAIN DEVELOPMENT AND FUNCTION
A series of studies over the past decade have revealed that finely-tuned miRNA function across the lifespan is critical for orchestrating cell proliferation, differentiation, migration, and death in the brain (Cheng, FIGURE 1 Schizophrenia GWAS meta-analysis regional association plot. A 400 kb region of chromosome 1 is shown, centered on the most significant SNP, rs1702294 (image from freeze PGC-SCZ52, https://data.broadinstitute.org/mpg/ricopili). The x-axis is genomic position, and the y-axis is degree of association with SCZ (−log 10 P Pastrana, Tavazoie, & Doetsch, 2009; Friedman et al., 2009; Hebert & De Strooper, 2007; Shibata, Nakao, Kiyonari, Abe, & Aizawa, 2011 number, synaptic efficiency, dendrite complexity, and context dependent short-term memory (Cheng et al., 2007; Edbauer et al., 2010; Hansen, Sakamoto, Wayman, Impey, & Obrietan, 2010; Impey et al., 2010; Remenyi et al., 2010; Wayman et al., 2008) . Beyond neurons, miRNAs control the differentiation and maintenance of glial cells in both the developing and mature brain (Hong, Jiang, & Li, 2014; Howng, Huang, Ptacek, & Fu, 2015; Kawase-Koga et al., 2009; Zhang et al., 2015) .
Dysregulation of miRNAs has been associated with several neurological and neuropsychiatric disorders (Beveridge et al., 2008; Klein et al., 2007; Kim et al., 2007; Packer, Xing, Harper, Jones, & Davidson, 2008; Shioya et al., 2010; Wang et al., 2008; Xu, Hsu, Karayiorgou, & Gogos, 2012; Xu, Li, Wang, & Gao, 2008; Zhou et al., 2009 (Merico et al., 2014; Sellier et al., 2014; Stark et al., 2008; Zhao et al., 2015) .
miR-137 was first identified in mice during tissue-specific small RNA profiling and was also shown to be highly conserved and expressed (chr1:98,453,556-98,515,249) . The 86bp hairpin sequence within pre-miR-137 is highly conserved from humans to zebrafish, representing ∼450 million years since the last common ancestor (Kumar & Hedges, 1998) . This illustrates that miR-137 has assumed a critical role in mammalian biology. In addition to the pre-miRNA sequence, there is also high evolutionary conservation of several key regulatory elements surrounding MIR137 (e.g., transcription factor binding sites, epigenetic marks, etc.), suggesting that some regulatory mechanisms may also be conserved. Figure 2 provides an overview of several of these features, many of which will be referred to in the discussion below. (Agarwal, Bell, Nam, & Bartel, 2015; Betel, Wilson, Gabow, Marks, & Sander, 2008; Wong & Wang, 2015) , 2) gene expression analysis after immunoprecipitating the RISC complex or after altering miR-137 expression (Boudreau et al., 2014; Collins et al., 2014; Hill et al., 2014; Tamim et al., 2014) , and 3) reporter gene activity or quantitative protein measures (e.g., luciferase assay, proteomics, Western blotting) (Chen, Wang et al., 2011; Kim et al., 2012; Kwon, Wang, & Tsai, 2013; Siegert et al., 2015) . Given the strengths and weaknesses of these various approaches, most investigators have chosen to integrate data from two or more of these methods in generating miR-137 target gene lists.
| miR-137 TARGET GENES AND SCHIZOPHRENIA GENOMICS
Bioinformatic algorithms predict miR-137 targets by calculating the likelihood of base-pairing with target mRNA untranslated regions (UTRs). The available algorithms vary in the weight given to different criteria for this calculation, and so their results vary. For example,
TargetScan searches primarily for a complementary match between the 3′ UTR of an mRNA and the miRNA "seed" sequence, which is the term given to the 5′ 2-8 nucleotides critical for target detection (Agarwal et al., 2015; Lewis, Burge, & Bartel, 2005) . In its latest version by Genovese et al. (2016) , who collated disruptive ultra-rare variants (dURVs) in exome sequencing data from Swedish SCZ cases and controls. In addition to observing an overall burden of dURVs in cases, they reported a significant enrichment within predicted miR-137 targets (Genovese et al., 2016) . Finally, taking an imaging genetics approach, Potkin et al. (2010) showed that miR-137 targets are enriched for smaller GWAS p-values in a study of dorsolateral prefrontal cortex (DLPFC) activation during a working memory task.
Experimentally derived miR-137 targets, from a variety of genomic approaches, have also been associated with schizophrenia. It is important to note that these studies, summarized below, employed a wide range of tissues, cell lines, expression platforms, and miR-137 manipulation methods. As a result, the overlap in miR-137 targets is limited, suggesting that miR-137 targets vary with tissue, cell type, and proliferative status (Boudreau et al., 2014; Collins et al., 2014; Hill et al., 2014; Tamim et al., 2014) . First, Collins et al. (2014) overexpressed miR-137 in the human neuroprogenitor cell line RenCell-VM and used RNA sequencing to nominate down-regulated genes as miR-137 targets.
They noted that several SCZ-related pathways were up-regulated 48 hr after miR-137 overexpression, including: calcium channels, synaptic proteins, FMRP-interacting RNAs, and genes forming the major histocompatibility complex (MHC). Second, Hill et al. (2014) took a FIGURE 2 Regulatory DNA surrounding MIR137. A number of key tracks from the UCSC Genome Browser (hg19 assembly) are shown. These include common SNPs (MAF > 0.05), with red arrows pointing to the lead SNP (rs1702294), previously detected lead SNP (rs1625579), and a potential MIR137 regulatory SNP (rs2660304). "VNTR" depicts the position of a putatively functional variable number tandem repeat (VNTR). The bindings sites for RE1-Silencing Transcription factor (REST) from two cell lines (ENCODE ChIP-seq data) are also shown. The "Txn Factor ChIP" track summarizes transcription factor ChIPseq data for 161 factors and the "DNase Clusters" track summarizes DNaseI hypersensitivity clusters in 125 cell types. "CpG Islands" shows regions with high CpG sequence frequency, while "Hypomethylation" shows regions with depleted DNA methylation in human neuronal progenitor cells. "H3K4me3" shows histone H3 Lysine 4 trimethylation (H3K4me3) sites, a marker associated with active transcription start sites, detected in postmortem human frontal cortex grey matter. "100 Vert. Cons" shows base-level conservation (PhyloP score) for 100 different vertebrate species. The red rectangles point to potential key transcription regulatory regions. similar approach in the human neural progenitor cell line CTXOE03, finding that genes down-regulated after miR-137 over-expression were enriched for involvement in neuronal differentiation and included genome-wide significant risk loci for SCZ (e.g., MAD1L1 and DPYD).
Interestingly, a recent study demonstrated that an increased polygenic risk score within the miR-137 targets that Hill et al. (2014) detected was associated with significantly lower performance on intelligence quotient, working memory and episodic memory (Cosgrove et al., 2017) . Functional brain imaging during a memory task further revealed that it is also associated with increased activation of the right inferior occipital gyrus (Cosgrove et al., 2017) . Third, Boudreau et al. (2014) used immunoprecipitation of the RISC complex from human brain motor cortex and cingulate gyrus to directly pull out mRNAs being actively targeted by miRNAs (HITS-CLIP). Expression analysis revealed 88 transcripts with miR-137 binding sites (TargetScan seeds), 24 of which overlapped with genes from a SCZ meta-analysis (SzGene database (Allen et al., 2008) ) or genes associated with prefrontal cortex abnormalities in psychiatric patients (Allen et al., 2008; Kim & Webster, 2010) . Of note, 5 SCZ GWAS associated genes including TCF4, a previously established miR-137 target (Kwon et al., 2013) , were included in this list (Boudreau et al., 2014) . Fourth, some groups have taken a proteomic approach to detect translationally regulated miR-137
targets (Hao et al., 2015; Ren et al., 2015; Schouten et al., 2015) , though their relevance to SCZ is as yet unclear.
Highly reliable miR-137 targets empirically demonstrated by molecular biological methods have been well summarized in previous reviews (Mahmoudi & Cairns, 2017; Wright et al., 2013 (Zeisel et al., 2015) that could be used to refine the role of this pathway in neuropsychiatric disorders.
| WHERE AND WHEN IS miR-137 EXPRESSED?
An examination of MIR137HG expression across >50 adult human tissues from GTEx (http://www.gtexportal.org) reveals highly enriched brain expression, with the highest expression in frontal cortex (Brodmann area 9, BA9) and this is supported by multiple publications (Consortium, 2015; Guo et al., 2014; Landgraf et al., 2007; Ludwig et al., 2016) . Nearly all tissues, however, show measurable expression of miR-137 in GTEx and there is a growing appreciation of the role miR-137 plays in the cell cycle and tumor formation in non-brain tissues (see below).
Regarding when miR-137 is expressed, it is becoming clear that it appears very early in development and is necessary for life. Crowley et al. (2015) showed that mice lacking expression of Mir137 (homozygous constitutive knockout) resulted in embryonic lethality before developmental day 11.5. Others have shown that miR-137 is expressed in mouse embryonic stem (ES) cells and regulates proper cell differentiation through specific target gene regulation (Jiang, Ren, & Nair, 2013; Tarantino et al., 2010) . According to Tarantino et al. (2010) 
| STEM CELL PROLIFERATION AND DIFFERENTIATION
SCZ is considered by some to be a neurodevelopmental disorder (Kinros, Reichenberg, & Frangou, 2010; Rapoport, Giedd, & Gogtay, 2012; Stachowiak et al., 2013) These reports demonstrate the pro-differentiation feature of miR-137 in embryonic neuronal stem cells.
In contrast to its effect on embryonic neurogenesis, Smrt et al. (2010) reported that miR-137 overexpression negatively controls adult neuronal stem cell differentiation. They confirmed that miR-137 targets are enriched in the neuronal lineage (compared to the astrocytic lineage) and that miR-137 is highly expressed in the adult dentate gyrus of the hippocampal formation, an area highly active in adult neurogenesis. Smrt However, consistent with the effect on the developing brain, Santos et al. (2016) showed that miR-137 is expressed much more highly in the nongerminal striatum than in the subventricular zone (SVZ, an area of adult neurogenesis) in 2-month-old mice and that miR-137 is upregulated during lineage progression and the differentiation of neural stem cells.
They further showed that overexpression of miR-137 in isolated neural stem cell cultures from 2-month-old mouse SVZ increases neuronal differentiation and decreases cell proliferation (Santos et al., 2016) . These results suggest that miR-137 has a context-dependent role and function during neuronal stem cell development. Given the diversity of predicted miR-137 targets in different cell types (Boudreau et al., 2014; Collins et al., 2014; Hill et al., 2014; Tamim et al., 2014) , it is not surprising that the miR-137 regulated gene network is dependent on cell lineage context. A
simple, yet important, methodological difference in these experiments included the magnitude of miR-137 overexpression, which may affect outcome. Again, we note that the use of a precise gene network analysis in individual cells could help to address these questions.
| NEURONAL MATURATION AND SYNAPTIC FUNCTION
A reduction of synaptic form and function are cellular features frequently observed in psychiatric disorders, including SCZ and autism (Garey et al., 1998; Glantz & Lewis, 2000; Glausier & Lewis, 2013) . Silber et al., 2008; Visani et al., 2014) . In fact, miR-137 expression in blood cells has been suggested as a biomarker for human glioblastoma (Li, Li, Li, Shi, & Chen, 2016) .
The effect of glial miR-137 on cognitive function, however, is poorly understood. Given the critical roles of glial cells in neurocognitive functions (Cotter, Pariante, & Everall, 2001; Dzyubenko, Gottschling, & Faissner, 2016; Jo, Law, & Chung, 2014; Stogsdill & Eroglu, 2016) and SCZ pathology (Bernstein, Steiner, Guest, Dobrowolny, & Bogerts, 2015) and the fact that some miR-137 target genes are expressed in glial cells (Tamim et al., 2014) , it would not be surprising if miR-137 mediated glial regulation has a critical role in finetuning brain function. For example, deficits in myelin, reduced oligodendrocytes, and altered expression of myelin/oligodendrocyte -related genes are found in SCZ, which could explain white matter abnormalities in SCZ (Goudriaan et al., 2014; Hof, Haroutunian, Copland, Davis, & Buxbaum, 2002; Kerns et al., 2010; Regenold et al., 2007; Schmitt et al., 2009; Uranova, Vikhreva, Rachmanova, & Orlovskaya, 2011 GABA, monoamines, and purines), may contribute to disturbed neurotransmission in SCZ (Bernstein et al., 2015; Sofroniew & Vinters, 2010) . In addition, microRNAs have been proven to have critical roles in glial cell development and function (Bian, Xu, & Sun, 2013; Karthikeyan, Patnala, Jadhav, Eng-Ang, & Dheen, 2016; Zheng, Li, Huang, & Qiu, 2012) . For example, miR-124 in microglia is downregulated during autoimmune inflammation of the CNS, and reduction of miR-124 in microglia activates these cells. (Ponomarev, Veremeyko, Barteneva, Krichevsky, & Weiner, 2011) . Interestingly, glial miR-137
shares a large number of putative targets with miR-124 (Schouten et al., 2015; Silber et al., 2008; Tamim et al., 2014) . In sum, although current knowledge of miR-137's role in glial cells is limited, these studies suggest potential functions of miR-137 in the fine tuning of brain function through glial cell regulation.
| ANIMAL MODELS OF miR-137 DYSFUNCTION
Mouse, fly, and fish all have models of miR-137 manipulation available for study. Crowley et al. (2015) reported that mice with a whole body knockout of Mir137 are embryonically lethal between embryonic days 4.5 and 11.5. Interestingly, heterozygous knockouts showed no striking behavioral phenotype, likely due to compensated miR-137 expression (Crowley et al., 2015) . Siegert et al. (2015) showed that virus-mediated miR-137 overexpression in the dentate gyrus impaired induction of mossy fiber long-term potentiation and induced a deficit in hippocampal-dependent learning and memory. In flies, knockout of Drosophila miR-1000 (ortholog of mammalian miR-137) led to an earlyonset movement disorder and higher apoptosis in the brain, as detected by Caspase-3 activity (Verma et al., 2015) . In fish, developmental suppression of miR-137 in zebrafish impaired both embryonic and larval touch-sensitivity without compromising overall anatomical development (Giacomotto et al., 2016) .
Given the severe phenotypes associated with loss of miR-137 in multiple species (particularly embryonic lethality in mice), there is a need for a conditional knockout of Mir137 in mice and other species. It will be important to examine the effects of miR-137 dysfunction at different developmental time-points, tissues, and cell types. Furthermore, only a few behavioral domains have been examined thus far (e.g., memory, anxiety, sensorimotor gating), but methods for other more sophisticated measures of various endophenotypes are improving (Achim et al., 2011; Hart et al., 2014; Nestler & Hyman, 2010; van Scheltinga et al., 2013; Winton-Brown, Fusar-Poli, Ungless, & Howes, 2014) .
| WHAT MOLECULAR MECHANISM(S) UNDERLIE THE MIR137 SCHIZOPHRENIA ASSOCIATION?
Common-variant GWAS associations for complex traits (like SCZ) are usually not explained by protein-coding variants but, on the other hand, they are often highly enriched for regulatory DNA (Hindorff et al., 2009 ).
Large-scale resources such as ENCODE (Consortium, 2012) have produced catalogs of putative regulatory DNA sequences, such as those with open chromatin, acetylated histones, enhancer function, or methylated DNA, to name but a few (see Figure 2) . In other disorders, there are documented examples of causal regulatory SNPs explaining GWAS signals (Fogarty, Cannon, Vadlamudi, Gaulton, & Mohlke, 2014; Nicolae et al., 2010; Smemo et al., 2014) . This has generated great interest in identifying variants in the MIR137 locus that may help explain the GWAS signal via altered expression, post-transcriptional processing or function of miR-137 (Consortium, 2015; Fromer et al., 2016; Gianfrancesco et al., 2016; Ward & Kellis, 2012; Yang, Li, Jiang, Zhou, & Qu, 2013) . Gianfrancesco et al. (2016) Jewish population (Duan et al., 2014; Goes et al., 2015) . It is important to state that, as of this writing, no genome-wide expression QTL (eQTL) study has associated rs2660304 with expression of MIR137, but few eQTL studies have closely examine microRNAs or their host genes and most brain eQTL studies at this point are underpowered. In sum, the existing in vitro molecular evidence appear consistent with at least one SCZ risk variant (rs2660304) being associated with reduced activity of the MIR137 promoter. Furthermore, another SCZ risk allele in this region, rs1625579, is associated with decreased miR-137 expression in the dorsolateral prefrontal cortex (DLPFC) (Guella et al., 2013) , providing convergent evidence.
Another putatively functional DNA variant found just upstream of MIR137 consists of a variable number tandem repeat (VNTR, see Figure 2 ). By overexpressing pre-miR-137 with various numbers of repeats (3-13) in HEK293 cells, Mamdani et al. (2013) demonstrated that pre-miR-137 carrying 9 and 13 repeats leads to significantly reduced miR-137 expression. Two additional studies provide evidence that VNTR length affects the secondary structure of pre-miR-137 stem-loop and impacts expression of mature miR-137 (Bemis et al., 2008; Strazisar et al., 2015) . While these findings suggest that VNTR repeat number potentially affects levels of miR-137, it is important to note that there is currently insufficient genetic evidence associating VNTR repeat length with SCZ, possibly due to the low allele frequency of the higher VNTR repeat, which reduces statistical power (Duan et al., 2014; Egawa et al., 2013; Strazisar et al., 2015; Warburton, Breen, Rujescu, Bubb, & Quinn, 2015) . MIR137 has been identified as a target gene of Repressor Element-1 Silencing Transcription Factor (REST) (Soldati et al., 2013; Warburton et al., 2015) , a key transcriptional regulator of neuron-specific genes (Ballas & Mandel, 2005; Ooi & Wood, 2007; Roopra, Huang, & Dingledine, 2001; Singh, Kagalwala, Parker-Thornburg, Adams, & Majumder, 2008; Tamminga & Zukin, 2015) . Soldati et al. (2013) showed that miR-137 expression is low in Huntington's disease model cells and that its expression increases after REST knockdown. Warburton et al. (2015) confirmed binding of REST to the miR-137 promoter by chromatin immunoprecipitation (ChIP). Given the potential involvement of REST in SCZ pathology, REST-mediated miR-137 regulation could be an important molecular mechanism (Tamminga & Zukin, 2015) .
Epigenetic mechanisms constitute another source of transcriptional regulation. miR-137 transcription is regulated by three hypomethylation sites (see Figure 2 ) (Kozaki et al., 2008; Song et al., 2013) . Several cancer cell studies have reported miR-137 expression modulation during altered DNA methylation (Chen, Wang et al., 2011; Silber et al., 2008; Zhu et al., 2013) . recruiting LSD1 to the miR-137 promoter .
Moreover, histone H3K4 demethylase Jarid1b (also known as KDM5b), which suppresses transcription through demethylation of transcription start sites, is also targeted by miR-137 during neuronal differentiation of mouse ES cells (Tarantino et al., 2010) . Together, these results suggest that epigenetic chromatin modulation is involved in a miR-137 self-regulation feedback loop.
In sum, a growing body of molecular studies are beginning to reveal functional DNA variants regulating MIR137 that may explain associations with SCZ. Other investigators are exploring the downstream gene network regulated by miR-137, including self-feedback.
Furthermore, recent studies have isolated physiological stimulators of MIR137, including metabotropic glutamate receptor stimulation, seizure activity, and propofal (Fan, Zhou, Qin, & Tao, 2016; Olde Loohuis et al., 2015; Schouten et al., 2015 (Baare et al., 2001; Samartzis, Dima, Fusar-Poli, & Kyriakopoulos, 2014; van Erp et al., 2016; Voineskos, 2015) . We have identified eight structural brain imaging studies (Cousijn et al., 2014; Kelly et al., 2014; Kuswanto et al., 2015; Lett et al., 2013; Li & Su, 2013; Patel et al., 2015; Rose et al., 2014; Wright et al., 2016) that specifically tested for an association between brain structure and variation in MIR137 (primarily the risk tagging SNP rs1625579). Kuswanto et al. (2015) found a significant interaction between MIR137 genotype and white matter integrity in the right orbitofrontal region of SCZ cases. Wright et al. (2016) found that SCZ subjects homozygous for the MIR137 risk allele showed significant decreases in occipital, parietal, and temporal lobe grey matter concentration. Lett et al. (2013) found that patients with the MIR137 risk genotype had reduced white matter integrity throughout the brain, smaller hippocampi, and larger lateral ventricles. The five other reports (Kelly et al., 2014; Li & Su, 2013; Patel et al., 2015; Rose et al., 2014; Wright et al., 2016) examined only healthy controls (with the exception of Rose et al. (2014) and Patel et al. (2015) who also included cases) and no clear association between the MIR137 variant and brain structure was found.
While the overall pattern of results are mixed and the number of studies is small, there may be a trend toward MIR137 exerting a greater influence in SCZ cases versus healthy controls.
Functional brain imaging studies have been also performed, most examining effects of the MIR137 risk SNP rs1625579 in healthy controls (Liu et al., 2014; Mothersill et al., 2014; van Erp et al., 2014; Whalley et al., 2012) . van Erp et al. (2014) found the risk genotype to be associated with higher left DLPFC activation. Similarly, Liu et al. (2014) showed that individuals homozygous for the risk allele exhibited significantly higher functional connectivity between DLPFC and left hippocampi than heterozygous individuals Further studies found that homozygous risk allele carriers had increased functional connectivity between the right amygdala and frontal regions (Mothersill et al., 2014) and higher activity in the posterior right medial frontal gyrus, BA6 (Whalley et al., 2012) . Although most of these studies used healthy controls, the results nonetheless demonstrate that individuals carrying MIR137 risk alleles tend to have higher activity in some brain areas.
In sum, despite relatively small sample sizes and the genotyping of only one MIR137 SCZ risk SNP, the existing brain imaging studies show some promise. Recently, the ENIGMA consortium reported a genomic association study for subcortical brain volume abnormalities in 2,028 SCZ and 2,540 healthy individuals . This initial subcortical-focused study did not find any association with MIR137, but larger studies incorporating cortical measures are underway.
| POTENTIAL FOR CLINICAL UTILITY
MicroRNAs are emerging as useful biomarkers and targets for therapeutic manipulation in complex diseases. Circulating miRNA levels in plasma, serum, and whole blood have shown potential as biomarkers of many disorders (Kawaguchi et al., 2016; Kosaka, Iguchi, & Ochiya, 2010; Witwer, 2015) including SCZ (Cairns, 2015; Kichukova, Popov, Ivanov, & Vachev, 2015; Wang, Wang, Yang, & Huang, 2014 Chistyakov, Nikitin, Konovalov, Potapov, Usachyov et al., 2014; Li et al., 2016 Li et al., , 2017 . Interestingly, Wu et al. (2016) recently demonstrated that miR-137 levels in peripheral blood cells may have potential for diagnosing early onset SCZ, though replication of this finding is needed. miR-137 transcription is regulated by the upstream hypomethylated CpG region (Kozaki et al., 2008; Song et al., 2013) , suggesting that DNA methylation status may be another potential biomarker (Gao, Zhang, Breitling, & Brenner, 2016; Henriksen, Madsen, Krarup, & Thorlacius-Ussing, 2015; Kozaki et al., 2008) . However, methylome-wide association studies of SCZ using blood cell DNA have not shown a significant association with miR-137 (Aberg et al., 2014; Dempster et al., 2011) .
Since miR-137 is known to modulate brain function, methods that manipulate miR-137 expression could have therapeutic potential in schizophrenia. miRNAs have been studied as a target of medications, and some specific miRNA modulators are currently being studied clinically. For example, antagomir-122, a chemically-modified antisense miR-122, is in Phase2 clinical trials for treating infection with hepatitis C virus (Lanford et al., 2010) . Likewise, a miR-21 inhibitor is undergoing a Phase1 trial for treatment of Alport syndrome, a kidney disease with no currently-approved therapy (Gomez et al., 2015) . In addition, MRX34, a double-stranded mimic of the naturally occurring tumor suppressor miR-34a, is being tested in a Phase1 trial for use with advanced solid tumors (Beg et al., 2014) .
It is theoretically possible that manipulating miR-137 expression with a chemically modified miR-137 inhibitor or mimic could have utility in SCZ.
There are, however, technical challenges that must be addressed, including achieving cell-type specificity and penetrating the blood-brain barrier (Krutzfeldt et al., 2005; Price & Chen, 2014; van Rooij, Purcell, & Levin, 2012; Zhang, Wang, & Gemeinhart, 2013) . To overcome both of these challenges simultaneously, virus-mediated delivery of a miR-137 modulator represents a compelling strategy. Working toward this goal, Murlidharan et al. (2016) recently established a neuron-specific adeno-associated virus capable of exclusively delivering a MIR137 specific guide RNA to neuronal cells for CRISPR/Cas9-targeted genome editing. Since, intravenous AAV injection can deliver genes to the brain (Murlidharan, Samulski, & Asokan, 2014; Schuster et al., 2014; Shen et al., 2013) , this strategy could be useful for the manipulation of miR-137 activity by delivering a miR-137 overexpression vector, an antisense inhibitor, or a MIR137 specific guide RNA capable of recruiting artificial transcription regulators (e.g., dCas9-VP16/-KRAB) to the MIR137 promoter in the neuronal cell (Genga, Kearns, & Maehr, 2016; Vora, Tuttle, Cheng, & Church, 2016) .
| CONCLUSIONS AND SUGGESTIONS FOR FUTURE RESEARCH
We have attempted to comprehensively review the genetic and biological evidence supporting a role for miR-137 in the etiology of SCZ. We conclude that the evidence is strong, but mechanistic details are lacking and, since SCZ is highly polygenic, at the level of the individual miR-137's role may be small. As noted in this review, however, miR-137 clearly regulates a number of other SCZ risk genes and therefore may represent an important signaling node within one or more SCZ-related gene networks. Without question, there is ample evidence to continue pursuing this gene and its associated network.
We believe that further investigations in several key areas are needed to fully appreciate the role of MIR137 in SCZ and test its diagnostic and therapeutic potential. First, on the genetic level, we suggest that future GWAS studies move beyond the case-control design, toward a "deep-phenotyping" symptom-dimension approach, integrating neurocognitive measures, environmental factors, etc as proposed by other investigators (Ehrenreich et al., 2016; Insel et al., 2010) . Second, on the molecular level, we think it is very important to definitively identify the causal genetic variant(s) underlying the SCZ GWAS association. As noted above, the last few years have witnessed marked progress in this area, but ever more advanced molecular methods are now available and could yield major insights. For example, allele-specific RNA sequencing in the brains of individuals heterozygous for SCZ-risk variants could clarify the direction of effect in this locus. Critically, these sequencing efforts should distinguish the host gene (MIR137HG) from the pre-miRNA and final, processed miRNA to tease apart transcriptional and post-transcriptional effects. Furthermore, these studies likely need to be performed across developmental stages and distinct cell types (e.g., using single-cell methods) to yield the most informative data. Third, the role of miR-137 in glial cells has been somewhat neglected in the pathological and non-pathological state, particularly given its role as a tumor suppressor in glioblastoma.
Fourth, given that human brain tissue is generally inaccessible, we believe improved genetic animal models will be a required to truly understand miR-137 from a mechanistic level. For example, given the embryonic lethality of the constitutive knockout mouse, there is an urgent need for a conditional knockout. Fifth, and finally, we suggest work toward improving methods for miR-137 manipulation in live animals to gauge utility as a therapeutic target and biomarker. These might include, for example, the development of brain-penetrating antagomirs, enhanced CRISPR/Cas9 mediated manipulation protocols or small molecules with specific effects on the miR-137 network. In conclusion, MIR137 remains a prominent SCZ risk gene with potential to open a window into the complex etiology of SCZ as the field works toward developing novel treatments for this devastating disorder.
